| # | Drug | Count |
|---|---|---|
| 0 | DICLOFENAC | 106 |
| 1 | DICLOFENAC SODIUM | 106 |
| 2 | RITUXIMAB | 101 |
| 3 | SECUKINUMAB | 101 |
| 4 | ADALIMUMAB-ADAZ | 100 |
| 5 | SULFASALAZINE | 100 |
| 6 | CERTOLIZUMAB PEGOL | 99 |
| 7 | GOLIMUMAB | 99 |
| 8 | DICLOFENAC SODIUM 1% | 95 |
| 9 | DICLOFENAC SODIUM TOPICAL | 95 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | HYDROCORTISONE BUTYRATE | 65 | 0.0329 |
| 1 | GOLD | 69 | 0.0119 |
| 2 | DICLOFENAC POTASSIUM TABLETS | 81 | 0.0093 |
| 3 | CHLORHEXIDINE GLUCONATE | 81 | 0.0087 |
| 4 | POVIDONE-IODINE | 34 | 0.0080 |
| 5 | GOLIMUMAB | 99 | 0.0079 |
| 6 | DICLOFENAC POTASSIUM | 81 | 0.0073 |
| 7 | PSEUDOEPHEDRINE HCL | 78 | 0.0071 |
| 8 | TOFACITINIB CITRATE | 81 | 0.0060 |
| 9 | BOTULINUM TOXIN TYPE A | 74 | 0.0058 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nonsteroidal Anti-inflammatory Drug [EPC] | 110 |
| 1 | Tumor Necrosis Factor Blocker [EPC] | 107 |
| 2 | Corticosteroid [EPC] | 106 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 101 |
| 4 | Interleukin-17A Antagonist [EPC] | 101 |
| 5 | Aminosalicylate [EPC] | 100 |
| 6 | Interleukin-6 Receptor Antagonist [EPC] | 95 |
| 7 | Antirheumatic Agent [EPC] | 92 |
| 8 | Selective T Cell Costimulation Modulator [EPC] | 91 |
| 9 | Vitamin C [EPC] | 91 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 80 | 0.1163 |
| 1 | Antiseptic [EPC] | 34 | 0.0078 |
| 2 | Interleukin-17A Antagonist [EPC] | 101 | 0.0027 |
| 3 | Medium-chain Triglyceride [EPC] | 1 | 0.0018 |
| 4 | beta3-Adrenergic Agonist [EPC] | 80 | 0.0017 |
| 5 | Provitamin D2 Compound [EPC] | 35 | 0.0012 |
| 6 | Aminosalicylate [EPC] | 100 | 0.0010 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 8 | 0.0009 |
| 8 | Antirheumatic Agent [EPC] | 92 | 0.0009 |
| 9 | Partial Opioid Agonist [EPC] | 74 | 0.0008 |